StudyGraphics #VisualAbstract GENUINE: Ublituximab and ibrutinib improved response in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia compared to ibrutinib monotherapy March 18, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #Visual Abstract Watchful waiting may be an appropriate strategy for some patients with basal cell carcinomas #VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas #VisualAbstract: Post-induction chemotherapy Epstein-Barr virus DNA is an effective prognostic indicator for nasopharyngeal carcinomas
